Abbott Labs

ABT-N

NYSE:ABT

94.92
2.82 (3.06%)
Abbott Laboratories is a multinational health care company with headquarters in Lake Bluff, Illinois.
More at Wikipedia

Analysis and Opinions about ABT-N

Signal
Opinion
Expert
PAST TOP PICK
PAST TOP PICK
February 4, 2014

(A Top Pick Feb 12/13. Up 7.44%.) Still likes this. Likes their branded pharmaceuticals division. Also, have diagnostics and nutritionals. Company increased their dividend by quite a large amount last quarter. Yield of about 2.5%. Trading at an attractive multiple.

Show full opinionHide full opinion
Abbott Labs (ABT-N)
February 4, 2014

(A Top Pick Feb 12/13. Up 7.44%.) Still likes this. Likes their branded pharmaceuticals division. Also, have diagnostics and nutritionals. Company increased their dividend by quite a large amount last quarter. Yield of about 2.5%. Trading at an attractive multiple.

DON'T BUY
DON'T BUY
January 29, 2014

Has really been falling. Results were a little mixed. Management was quite cautious and said the 2nd half was going to be a challenging time, partly because of difficult comparisons and partly because of the stronger US$. He just doesn’t see a catalyst and the price is a little too high for him.

Show full opinionHide full opinion
Abbott Labs (ABT-N)
January 29, 2014

Has really been falling. Results were a little mixed. Management was quite cautious and said the 2nd half was going to be a challenging time, partly because of difficult comparisons and partly because of the stronger US$. He just doesn’t see a catalyst and the price is a little too high for him.

BUY
BUY
January 2, 2014

A good stable company. Sold his holdings when they spun off their pharmaceutical division. They are now left with medical devices, nutritional business and their diagnostic business. Have a wonderful record of growing dividends over the years. Very steady and he feels it is underappreciated.

Show full opinionHide full opinion
Abbott Labs (ABT-N)
January 2, 2014

A good stable company. Sold his holdings when they spun off their pharmaceutical division. They are now left with medical devices, nutritional business and their diagnostic business. Have a wonderful record of growing dividends over the years. Very steady and he feels it is underappreciated.

COMMENT
COMMENT
December 23, 2013

Sold his holdings a few months ago in order to look for other opportunities. Valuations are a little too excessive for him. He prefers to buy in the 12-13 times earnings range. Doesn’t see growth in this one.

Show full opinionHide full opinion
Abbott Labs (ABT-N)
December 23, 2013

Sold his holdings a few months ago in order to look for other opportunities. Valuations are a little too excessive for him. He prefers to buy in the 12-13 times earnings range. Doesn’t see growth in this one.

TOP PICK
TOP PICK
December 9, 2013

Spun off drug side. It is medical devices and has been one of the most consistent growers over the last decade. Reasonably priced, 2.5% yield.

Show full opinionHide full opinion
Abbott Labs (ABT-N)
December 9, 2013

Spun off drug side. It is medical devices and has been one of the most consistent growers over the last decade. Reasonably priced, 2.5% yield.

PAST TOP PICK
PAST TOP PICK
November 29, 2013

(A Top Pick Nov 26/12. Up 24.63%.) There was a spin out of Abbvie (ABBV-N) from this company

Show full opinionHide full opinion
Abbott Labs (ABT-N)
November 29, 2013

(A Top Pick Nov 26/12. Up 24.63%.) There was a spin out of Abbvie (ABBV-N) from this company

TOP PICK
TOP PICK
November 1, 2013

Bought this because he was looking to increase his exposure to healthcare. Not that expensive. Nice diverse portfolio. Good exposure, both in North America and outside. Could be $42 over 12 months.

Show full opinionHide full opinion
Abbott Labs (ABT-N)
November 1, 2013

Bought this because he was looking to increase his exposure to healthcare. Not that expensive. Nice diverse portfolio. Good exposure, both in North America and outside. Could be $42 over 12 months.

PAST TOP PICK
PAST TOP PICK
October 30, 2013

(A Top Pick Nov 19/12. Up 25.37%.) Spun off their branded pharmaceutical business last year and he offloaded the AbVie (ABBV-N) component and kept this part that was more focused on medical devices and nutritions. Still likes. Increased their dividend by 57%. Most recent quarter showed that they had made 2 acquisitions on the medical devices side in cataract surgery equipment. 3.2% dividend yield.

Show full opinionHide full opinion
Abbott Labs (ABT-N)
October 30, 2013

(A Top Pick Nov 19/12. Up 25.37%.) Spun off their branded pharmaceutical business last year and he offloaded the AbVie (ABBV-N) component and kept this part that was more focused on medical devices and nutritions. Still likes. Increased their dividend by 57%. Most recent quarter showed that they had made 2 acquisitions on the medical devices side in cataract surgery equipment. 3.2% dividend yield.

TOP PICK
TOP PICK
October 29, 2013

Adult and infant nutritionals. Generics, very emerging market focused, diversified. Good earnings growth going forward. Very shareholder friendly. Increasing dividend should attract more shareholders.

Show full opinionHide full opinion
Abbott Labs (ABT-N)
October 29, 2013

Adult and infant nutritionals. Generics, very emerging market focused, diversified. Good earnings growth going forward. Very shareholder friendly. Increasing dividend should attract more shareholders.

PAST TOP PICK
PAST TOP PICK
October 10, 2013

(Top Pick Oct 11/12, Up 2.37%) Did well with Abvie as well. He sold ABT.

Show full opinionHide full opinion
Abbott Labs (ABT-N)
October 10, 2013

(Top Pick Oct 11/12, Up 2.37%) Did well with Abvie as well. He sold ABT.

HOLD
HOLD
October 4, 2013

Sold his holdings before the spinoff of their pharmaceutical side into AbbVie (ABBV-N). They are left with the nutritional, diagnostics and medical devices. Trading at about 14 or 15 times earnings. Growing at 11%-13% per year. Very, very stable company and a great core position in your portfolio.

Show full opinionHide full opinion
Abbott Labs (ABT-N)
October 4, 2013

Sold his holdings before the spinoff of their pharmaceutical side into AbbVie (ABBV-N). They are left with the nutritional, diagnostics and medical devices. Trading at about 14 or 15 times earnings. Growing at 11%-13% per year. Very, very stable company and a great core position in your portfolio.

TOP PICK
TOP PICK
September 19, 2013

Diversified healthcare company. Recently spun off their pharmaceutical business. Has some decent growth over the next couple of years. Thinks it can get to $42 over a 12-18 time period.

Show full opinionHide full opinion
Abbott Labs (ABT-N)
September 19, 2013

Diversified healthcare company. Recently spun off their pharmaceutical business. Has some decent growth over the next couple of years. Thinks it can get to $42 over a 12-18 time period.

PAST TOP PICK
PAST TOP PICK
September 18, 2013

(A Top Pick Sept 4/12. Up 13.65%.) He would like to add to his holdings when he gets the opportunity.

Show full opinionHide full opinion
Abbott Labs (ABT-N)
September 18, 2013

(A Top Pick Sept 4/12. Up 13.65%.) He would like to add to his holdings when he gets the opportunity.

TOP PICK
TOP PICK
July 29, 2013

Just moved up stop loss to $34.90 (200 day moving average). They are in the right space. Nutritional component looks to be just in the beginning of a long term uptrend.

Show full opinionHide full opinion
Abbott Labs (ABT-N)
July 29, 2013

Just moved up stop loss to $34.90 (200 day moving average). They are in the right space. Nutritional component looks to be just in the beginning of a long term uptrend.

TOP PICK
TOP PICK
July 9, 2013

Spun off their branded pharmaceutical business last year so now they have 40% in emerging markets and aiming to take closer to 50% over the next couple of years. Have some nutritional products along with their stents. Likes the product pipeline. Playing the increased demand for healthcare products in emerging markets through their branded generics. Continuing to see improved margins. Very attractive entry point. Yield of 1.6%.

Show full opinionHide full opinion
Abbott Labs (ABT-N)
July 9, 2013

Spun off their branded pharmaceutical business last year so now they have 40% in emerging markets and aiming to take closer to 50% over the next couple of years. Have some nutritional products along with their stents. Likes the product pipeline. Playing the increased demand for healthcare products in emerging markets through their branded generics. Continuing to see improved margins. Very attractive entry point. Yield of 1.6%.

Showing 46 to 60 of 122 entries